81088 Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices 

organizations; private-sector entities; 

researchers and academic institutions; 

people living with and who experience 

risk for disease; and other interested 

constituents on Strategic Plans to serve 

as national roadmaps to guide efforts to 

address HIV, sexually transmitted 

infections (STI), and viral hepatitis, and 

to improve and enhance the 

development and use of vaccines in the 

United States. 

DATES: To be assured consideration, 

comments must be received at the 

addresses provided below, no later than 

5:00 p.m. ET on December 6, 2024. 

ADDRESSES: Submissions must be 

submitted electronically via the 

following website: https://

app.smartsheetgov.com/b/form/ 

68aa1bd9c54b42829f99e85cc4ab1e82. 

FOR FURTHER INFORMATION CONTACT: 

Questions about this RFI should be 

directed to Nathan Fecik; Phone: 202– 

795–7616; Email: Syndemics@hhs.gov. 

SUPPLEMENTARY INFORMATION: OIDP 

requests feedback on the development 

of the following (collectively referred to 

as the Strategic Plans): 

• National HIV/AIDS Strategy for the 

United States: 2026–2030 (NHAS) 

• Sexually Transmitted Infections 

National Strategic Plan for the United 

States: 2026–2030 (STI Plan) 

• Vaccines National Strategic Plan for 

the United States: 2026–2030 

(Vaccines Plan) 

• Viral Hepatitis National Strategic Plan 

for the United States 2026–2030 (Viral 

Hepatitis Plan) 

The National HIV/AIDS Strategy for 

the United States: 2022–2025 (https://

files.hiv.gov/s3fs-public/NHAS-2022- 

2025.pdf), the Sexually Transmitted 

Infections National Strategic Plan for the 

United States: 2021–2025 (https://

www.hhs.gov/sites/default/files/STINational-Strategic-Plan-2021-2025.pdf), 

the Vaccines National Strategic Plan: 

2021–2025 (https://www.hhs.gov/sites/ 

default/files/HHS-Vaccines-Report.pdf), 

and the Viral Hepatitis National 

Strategic Plan for the United States: A 

Roadmap to Elimination: 2021–2025 

(https://www.hhs.gov/sites/default/files/ 

Viral-Hepatitis-National-Strategic-Plan2021-2025.pdf) expire at the end of 

calendar year 2025. 

OIDP, in collaboration with the White 

House Office of National AIDS Policy 

(focused specifically on the NHAS) and 

Federal partners, is leading work to 

develop the next iteration of these 

interrelated Strategic Plans through 

2030. As the next NHAS will be 

developed in parallel with the three 

national strategic plans, OIDP is 

collecting information for the 2026– 

2030 National HIV/AIDS Strategy at the 

request of the White House Office of 

National AIDS Policy. OIDP invites 

community input as people have served 

as the cornerstone for developing the 

Strategic Plans since their inception. 

Background: The Strategic Plans serve 

as national roadmaps for a broad range 

of constituents to help prevent, 

diagnose, treat, and cure disease, 

improve health outcomes, reduce health 

disparities and inequities, and advance 

research and technology. The plans 

include a common vision, overarching 

goals, objectives, and strategies, and 

indicators to measure national progress 

toward established targets. 

The development of the next iteration 

of the Strategic Plans will serve as an 

opportunity to incorporate the latest 

epidemiological data; review progress 

toward achieving national strategic plan 

goals; center the needs of populations 

disproportionately affected; address 

gaps identified in existing Strategic 

Plans; integrate the latest scientific 

advances; prioritize the most effective 

strategies for achieving national goals; 

and further emphasize the need to 

implement integrated syndemic 

approaches (https://www.hiv.gov/blog/ 

defining-the-term-syndemic) that cut 

across each of the Strategic Plans and 

address common root causes of 

infectious diseases. 

OIDP, in collaboration with Federal 

partners, is updating the Strategic Plans 

at the same time because these 

conditions often disproportionately 

affect similar populations and may 

share common root causes. The Vaccine 

National Strategic Plan is included in 

this coordinated process to elevate the 

critical role vaccines can serve as a key 

intervention to prevent infectious 

disease, including STIs and viral 

hepatitis, and to disrupt syndemics. By 

updating the Strategic Plans at the same 

time, OIDP aims to identify, leverage, 

and maximize Federal and other 

resources to achieve health equity and 

reduce related health disparities. 

OIDP coordinates the development, 

implementation, and monitoring of the 

Strategic Plans in collaboration with 

Federal partners. 

Information Requested: Anyone can 

submit written responses to the 

questions of interest listed at the 

following website: https://

app.smartsheetgov.com/b/form/ 

68aa1bd9c54b42829f99e85cc4ab1e82. 

This feedback will inform the 2026– 

2030 Strategic Plans. Please note that 

responses have specified word limits. 

Please provide evidence-based 

justification where applicable. 

Professional societies, advocacy 

organizations, and other groups are 

encouraged to submit a single collective 

response that reflects the views of their 

membership. 

Responses to this RFI Notice are 

voluntary and may be made public by 

HHS. The submitted information will be 

reviewed by HHS staff and may be made 

available to the public, along with the 

submitting individual’s name, email 

address, and demographic information 

consisting of the submitter’s location, 

affiliated organization, role, and (if 

provided) title and nature of comments. 

Submitted information will not be 

considered confidential, so do not 

include proprietary, classified, 

confidential, personal, or other sensitive 

information in your response. This 

request is for information and planning 

purposes and should not be construed 

as a solicitation or as an obligation of 

the Federal Government or the HHS. No 

awards will be made based on responses 

to this RFI. The information submitted 

will be analyzed and may be used in 

reports or presentations. Those who 

respond are advised that the HHS is 

under no obligation to acknowledge 

receipt of your comments or provide 

feedback on your submission. The HHS 

and the government reserve the right to 

use any non-proprietary technical 

information in any future solicitation(s). 

Authority: 42 U.S.C. 202 and 42 

U.S.C. 207. 

B. Kaye Hayes, 

Deputy Assistant Secretary for Infectious 

Disease; Director, Office of Infectious Disease 

and HIV/AIDS Policy. 

[FR Doc. 2024–22948 Filed 10–4–24; 8:45 am] 

BILLING CODE P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; 60-Day Comment 

Request; Collection of Customer 

Service, Demographic, and Smoking/ 

Tobacco Use Information From the 

National Cancer Institute’s (NCI) 

Cancer Information Service (CIS) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: In compliance with the 

requirement of the Paperwork 

Reduction Act of 1995 to provide an 

opportunity for public comment on 

proposed data collection projects, the 

National Cancer Institute (NCI) will 

publish periodic summaries of proposed 

projects to be submitted to the Office of 

Management and Budget (OMB) for 

review and approval. 


lotter on DSK11XQN23PROD with NOTICES1
Federal Register / Vol. 89, No. 194 / Monday, October 7, 2024 / Notices 81089 

DATES: Comments regarding this 

information collection are best assured 

of having their full effect if received 

within 60 days of the date of this 

publication. 

FOR FURTHER INFORMATION CONTACT: To 

obtain a copy of the data collection 

plans and instruments, submit 

comments in writing, or request more 

information on the proposed project, 

contact Candace Maynard, Branch 

Chief, Cancer Information Service 

Branch, CISB/OCPL, 9609 Medical 

Center Drive, Rockville, MD 20850, or 

call non-toll-free number 240–276–6657 

or email your request, including your 

address to: deatonc@mail.nih.gov. 

Formal requests for additional plans and 

instruments must be requested in 

writing. 

SUPPLEMENTARY INFORMATION: Section 

3506(c)(2)(A) of the Paperwork 

Reduction Act of 1995 requires written 

comments and/or suggestions from the 

public, and affected agencies are invited 

to address one or more of the following 

points: (1) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

function of the agency, including 

whether the information will have 

practical utility; (2) The accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information, 

including the validity of the 

methodology and assumptions used; (3) 

Ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (4) Ways to minimize the 

burden of the collection of information 

on those who are to respond, including 

the use of appropriate automated, 

electronic, mechanical, or other 

technological collection techniques or 

other forms of information technology. 

Proposed Collection Title: Collection 

of Customer Service, Demographic, and 

Smoking/Tobacco use Information from 

the National Cancer Institute’s (NCI) 

Cancer Information Service (CIS), 0925– 

0208, Expiration Date 03/31/2025, 

REVISION, National Cancer Institute 

(NCI), National Institutes of Health 

(NIH). 

Need and Use of Information 

Collection: The National Cancer 

Institute (NCI) currently collects (1) 

customer service and demographic 

information from clients of the Cancer 

Information Service (CIS) to properly 

plan, implement, and evaluate cancer 

education efforts, including assessing 

the extent by which the CIS reaches and 

impacts underserved populations; (2) 

smoking/tobacco use behavior of 

individuals seeking NCI’s smoking 

cessation assistance through the CIS to 

provide smoking cessation services 

tailored to the individual client’s needs 

and track their smoking behavior at 

follow up. This is a request for OMB to 

approve a revised submission for an 

additional three years to provide 

ongoing customer service collection of 

demographic information and collection 

of brief customer satisfaction questions 

from NCI Cancer Information Service 

Clients for the purpose of program 

planning and evaluation. 

OMB approval is requested for 3 

years. Respondents’ only cost is their 

time. The total estimated annualized 

burden hours are 6,343. 

ESTIMATED ANNUALIZED BURDEN HOURS

Form name Category of respondent Number of 

respondents 

Number of 

responses per 

respondent 

Average time 

per response 

(in hours) 

Total annual 

burden hours 

Demographic & Customer Satisfaction Questions 

(Appendix 1A or 1AB).

Individuals ..................... 15,754 1 3/60 788 

Demographic & Customer Satisfaction Questions 

(Appendix 1B).

Individuals ..................... 17,589 1 2/60 586 

Smoking Cessation ‘‘Intake’’ Questions (Appendix 1C).Individuals ..................... 8,839 1 6/60 884 

Smoking Call Backs (Appendix 1D) ..................... Individuals ..................... 8,840 1 4/60 589 

VA Call Backs (Appendix 1E) ............................... Individuals ..................... 26,055 1 4/60 1,737 

Cancer Info Call Backs (Appendix 1F) ................. Individuals ..................... 1,841 1 4/60 123 

Email Intake Form (Appendix 2) ........................... Individuals ..................... 9,740 1 10/60 1,623 

Demographic & Customer Satisfaction Questions 

(Appendix 9).

Individuals ..................... 400 1 2/60 13 

Totals ............................................................. ....................................... ........................ 113,191 ........................ 6,343 

Dated: October 2, 2024. 

Diane Kreinbrink, 

Project Clearance Liaison, National Cancer 

Institute, National Institutes of Health. 

[FR Doc. 2024–23127 Filed 10–4–24; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Anti-KK–LC–1 T Cell 

Receptors 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Cancer Institute, 

an institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patents and Patent Applications listed 

in the Supplementary Information 

section of this notice to T-Cure 

Biosciences, Inc. (‘‘T-Cure’’) located in 

Calabasas, California. 

DATES: Only written comments and/or 

applications for a license which are 

received by the National Cancer 

Institute’s Technology Transfer Center 

on or before October 22, 2024 will be 

considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Suna Gulay French, Ph.D., 

Technology Transfer Manager, NCI 


lotter on DSK11XQN23PROD with NOTICES1